PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2,...
Hence then, the article about taiho oncology and cullinan therapeutics announce pivotal rezilient1 phase 1 2 data published in the journal of clinical oncology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology )
Also on site :
- Inflatable Tanning Pool Loungers Are Going Viral, and Amazon’s ‘Super Comfy’ $28 Version Is a Shopper Favorite
- Quote of the Day: French Novelist Marcel Proust on Gratitude and the People Who Make Our Souls Blossom
- Valmet delivers board making line and lifecycle support to Sun Paper in China, enabling energy- and resource-efficient production